Athira Pharma to Present at Stifel’s 3rd Annual CNS Conference

Rhea-AI Summary

Athira Pharma (NASDAQ: ATHA), a biopharmaceutical company focused on neuronal health, announced that its CEO, Leen Kawas, will participate in a virtual fireside chat at Stifel’s 3rd Annual CNS Conference on April 1, 2021, at 9:00 am ET. The event will be accessible via a live webcast on Athira's investor relations website, with an archived replay available for 90 days post-event. Athira is advancing its lead candidate, ATH-1017, targeting Alzheimer's and Parkinson's dementia, aiming to alter the course of neurological diseases and enhance cognitive abilities.

BOTHELL, Wash., March 24, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at Stifel’s 3^rd Annual CNS Conference on Thursday, April 1, 2021, at 9:00 am ET.

A live webcast of the fireside chat will also be available on the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations. An archived replay of the webcast will be available for approximately 90 days following the event.

About Athira Pharma, Inc.
Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer’s and Parkinson’s dementia. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.

Investor & Media Contact:
Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219

FAQ

When will Athira Pharma participate in the Stifel CNS Conference?

Athira Pharma will participate in Stifel’s 3rd Annual CNS Conference on April 1, 2021, at 9:00 am ET.

Who will be representing Athira Pharma at the CNS Conference?

Leen Kawas, Ph.D., President and CEO, will represent Athira Pharma at the conference.

Is there a way to listen to the Athira fireside chat?

Yes, a live webcast of the fireside chat will be available on Athira's investor relations website.

How long will the archived replay of the fireside chat be available?

The archived replay will be accessible for approximately 90 days after the event.

What is the focus of Athira Pharma's research and development?

Athira Pharma focuses on developing small molecules to restore neuronal health and treat neurodegeneration.

What is Athira's lead therapeutic candidate?

Athira's lead candidate is ATH-1017, aimed at addressing Alzheimer's and Parkinson's dementia.